Mildronate (Meldonium Dihydrate)

Meldonium inhibits the synthesis of carnitine, a molecule essential for transporting long‑chain fatty acids into mitochondria for oxidation. By lowering carnitine levels, the drug reduces fatty‑acid oxidation and promotes glucose oxidation, a more oxygen‑efficient energy pathway for heart muscle, especially during periods of limited blood flow.

The dosage of Mildronate is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, severity of disease, renal function and other medications. Physicians set the appropriate dose and schedule according to current medical guidelines.

Safety data for Meldonium in pregnancy and lactation are limited. Because potential risks cannot be ruled out, it should only be used if the prescriber judges that the potential benefit outweighs any possible harm to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mildronate. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.

Mildronate differs from traditional anti‑anginal drugs such as nitrates or beta‑blockers because it targets myocardial energy metabolism rather than vascular tone. Compared with other metabolic modulators, Meldonium’s primary mechanism is carnitine inhibition, which can provide a complementary approach for patients who remain symptomatic despite standard therapy.

Mildronate should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

Mildronate is administered orally, typically in tablet or capsule form. The exact route of administration is by mouth, and patients should follow the prescriber’s instructions regarding timing, whether to take it with food or on an empty stomach, and any required fluid intake.

Serious risks, although rare, include cardiac arrhythmias, severe hypotension, allergic reactions such as rash or anaphylaxis, and liver enzyme elevations that may indicate hepatic injury. Patients should be monitored for these events, especially during treatment initiation or dose adjustments.

Mildronate is contraindicated in individuals with known hypersensitivity to Meldonium or any of the product’s excipients. Caution is advised for patients with severe renal impairment, uncontrolled hypertension, or those taking medications that may interact significantly, such as MAO inhibitors or strong CYP450 inhibitors.